{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:45:12Z","timestamp":1793832312636,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.jemermed.2005.01.033","type":"journal-article","created":{"date-parts":[[2006,1,27]],"date-time":"2006-01-27T09:54:49Z","timestamp":1138355689000},"page":"41-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Serum sickness-like reactions in patients receiving intravenous infliximab"],"prefix":"10.1016","volume":"30","author":[{"given":"Roberto M.","family":"Gamarra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"McGraw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma S.","family":"Drelichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis C.","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jemermed.2005.01.033_bib1","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1111\/j.1572-0241.2002.07093.x","article-title":"Infliximab in the treatment of Crohn\u2019s disease","volume":"97","author":"Sandborn","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jemermed.2005.01.033_bib2","first-page":"2525","article-title":"The use of Infliximab in academic rheumatology practice","volume":"29","author":"Fitzcharles","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jemermed.2005.01.033_bib3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of RA","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2005.01.033_bib4","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor (alpha) monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jemermed.2005.01.033_bib5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2005.01.033_bib6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","article-title":"Repeated therapy with monoclonal antibody to tumor necrosis factor-alpha (cA2) in patients with rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2005.01.033_bib7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor (alpha) for Crohn\u2019s disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2005.01.033_bib8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2005.01.033_bib9","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.jemermed.2005.01.033_bib10","first-page":"S1980","article-title":"54-week clinical and radiographic results from the ATTRACT trial","volume":"42","author":"Lipsky","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jemermed.2005.01.033_bib11","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-alpha","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jemermed.2005.01.033_bib12","series-title":"Remicade (infliximab) for IV injection. Package insert","year":"2002"},{"key":"10.1016\/j.jemermed.2005.01.033_bib13","first-page":"S465","article-title":"The diagnosis and management of anaphylaxis. Joint Task force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology","volume":"101","year":"1998","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl","key":"10.1016\/j.jemermed.2005.01.033_bib14","first-page":"S1801","article-title":"Successful treatment of severe psoriatic arthritis with infliximab","volume":"42","author":"Antoni","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jemermed.2005.01.033_bib15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab","volume":"359","author":"Braun","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2005.01.033_bib16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/120347540000400411","article-title":"Serum sickness","volume":"4","author":"Jackson","year":"2000","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jemermed.2005.01.033_bib17","first-page":"105","article-title":"Serum sickness","volume":"56","author":"Erffmeyer","year":"1986","journal-title":"Ann Allergy"},{"key":"10.1016\/j.jemermed.2005.01.033_bib18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/infdis\/158.2.474","article-title":"Serum sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim-sulfamethoxazole","volume":"158","author":"Platt","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jemermed.2005.01.033_bib19","first-page":"A731","article-title":"Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2\u20134 year interval without treatment","volume":"116","author":"Hanauer","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jemermed.2005.01.033_bib20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C","article-title":"Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)","volume":"44","author":"D\u2019Arcy","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jemermed.2005.01.033_bib21","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jemermed.2005.01.033_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0889-857X(02)00101-1","article-title":"Infection complications associated with the use of biologic agents","volume":"29","author":"Bresnihan","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jemermed.2005.01.033_bib23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jemermed.2005.01.033_bib24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","article-title":"Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy","volume":"167","author":"Wood","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jemermed.2005.01.033_bib25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","article-title":"Anti-TNF-alpha-induced systemic lupus syndrome","volume":"22","author":"Debandt","year":"2003","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jemermed.2005.01.033_bib26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1191\/0961203302lu236cr","article-title":"Drug-induced lupus following treatment with infliximab in rheumatoid arthritis","volume":"11","author":"Favalli","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.jemermed.2005.01.033_bib27","doi-asserted-by":"crossref","first-page":"E183","DOI":"10.1161\/01.CIR.0000017216.41471.DF","article-title":"Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab","volume":"105","author":"de\u2019 Clari","year":"2002","journal-title":"Circulation"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467905003550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467905003550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:15:33Z","timestamp":1760026533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467905003550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0736467905003550"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2005.01.033","relation":{},"ISSN":["0736-4679"],"issn-type":[{"value":"0736-4679","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum sickness-like reactions in patients receiving intravenous infliximab","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2005.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}